Concepts (126)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alzheimer Disease | 31 | 2024 | 327 | 9.150 |
Why?
|
| tau Proteins | 18 | 2024 | 41 | 2.850 |
Why?
|
| Dementia | 8 | 2024 | 252 | 2.250 |
Why?
|
| Amyloidosis | 5 | 2023 | 14 | 1.670 |
Why?
|
| Humans | 58 | 2024 | 32005 | 1.410 |
Why?
|
| Ovariectomy | 3 | 2024 | 166 | 1.320 |
Why?
|
| Aging | 10 | 2024 | 946 | 1.300 |
Why?
|
| Female | 35 | 2024 | 19959 | 1.240 |
Why?
|
| Estrogens | 3 | 2024 | 180 | 1.220 |
Why?
|
| Brain | 11 | 2024 | 951 | 1.200 |
Why?
|
| Neurofilament Proteins | 2 | 2024 | 13 | 1.180 |
Why?
|
| Aged | 27 | 2024 | 10301 | 1.160 |
Why?
|
| Cerebrovascular Disorders | 2 | 2024 | 52 | 1.120 |
Why?
|
| Hypertension, Pregnancy-Induced | 2 | 2023 | 13 | 1.090 |
Why?
|
| Sex Characteristics | 4 | 2023 | 173 | 1.060 |
Why?
|
| Pre-Eclampsia | 2 | 2023 | 66 | 1.030 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2024 | 29 | 0.950 |
Why?
|
| Premenopause | 1 | 2024 | 44 | 0.940 |
Why?
|
| Analgesics, Opioid | 2 | 2024 | 232 | 0.900 |
Why?
|
| Ceramides | 1 | 2023 | 10 | 0.890 |
Why?
|
| Positron-Emission Tomography | 8 | 2024 | 163 | 0.880 |
Why?
|
| Arthritis | 1 | 2023 | 40 | 0.870 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2023 | 58 | 0.870 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2023 | 37 | 0.860 |
Why?
|
| Gender Identity | 2 | 2023 | 23 | 0.860 |
Why?
|
| Middle Aged | 18 | 2024 | 11817 | 0.850 |
Why?
|
| Cognition | 6 | 2023 | 555 | 0.840 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2024 | 1328 | 0.820 |
Why?
|
| Risk Factors | 12 | 2023 | 3876 | 0.800 |
Why?
|
| Parkinson Disease | 1 | 2022 | 87 | 0.770 |
Why?
|
| Interleukin-6 | 1 | 2022 | 247 | 0.760 |
Why?
|
| Biological Products | 1 | 2022 | 77 | 0.750 |
Why?
|
| Cohort Studies | 7 | 2024 | 1817 | 0.740 |
Why?
|
| Male | 25 | 2024 | 19165 | 0.720 |
Why?
|
| Glial Fibrillary Acidic Protein | 3 | 2024 | 41 | 0.710 |
Why?
|
| Longitudinal Studies | 5 | 2024 | 767 | 0.680 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2022 | 291 | 0.640 |
Why?
|
| Chronic Disease | 4 | 2023 | 406 | 0.630 |
Why?
|
| Breast Neoplasms | 1 | 2022 | 765 | 0.520 |
Why?
|
| Cross-Sectional Studies | 9 | 2024 | 1531 | 0.470 |
Why?
|
| Life Style | 3 | 2024 | 408 | 0.400 |
Why?
|
| Rural Population | 2 | 2024 | 274 | 0.380 |
Why?
|
| Adult | 7 | 2024 | 9345 | 0.360 |
Why?
|
| Diabetes Mellitus | 2 | 2024 | 411 | 0.340 |
Why?
|
| Aged, 80 and over | 7 | 2024 | 3990 | 0.310 |
Why?
|
| Amyloid | 3 | 2022 | 15 | 0.310 |
Why?
|
| Verbal Learning | 2 | 2024 | 8 | 0.290 |
Why?
|
| Sex Factors | 3 | 2024 | 663 | 0.270 |
Why?
|
| Anisotropy | 1 | 2024 | 11 | 0.240 |
Why?
|
| Reproductive History | 1 | 2024 | 5 | 0.240 |
Why?
|
| Adrenocortical Adenoma | 1 | 2023 | 2 | 0.230 |
Why?
|
| Disease Progression | 2 | 2023 | 594 | 0.230 |
Why?
|
| Memory Disorders | 2 | 2024 | 54 | 0.230 |
Why?
|
| Phosphorylation | 1 | 2024 | 229 | 0.220 |
Why?
|
| Independent Living | 1 | 2024 | 99 | 0.220 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2024 | 112 | 0.220 |
Why?
|
| Adenoma | 1 | 2023 | 35 | 0.220 |
Why?
|
| Biological Specimen Banks | 1 | 2023 | 8 | 0.220 |
Why?
|
| Loneliness | 1 | 2023 | 9 | 0.220 |
Why?
|
| Hysterectomy | 1 | 2023 | 46 | 0.220 |
Why?
|
| Locus Coeruleus | 1 | 2022 | 18 | 0.210 |
Why?
|
| Social Class | 1 | 2023 | 89 | 0.210 |
Why?
|
| Pregnancy | 2 | 2023 | 997 | 0.210 |
Why?
|
| Prescriptions | 1 | 2022 | 12 | 0.210 |
Why?
|
| Apolipoproteins E | 1 | 2023 | 95 | 0.210 |
Why?
|
| Learning | 1 | 2023 | 79 | 0.210 |
Why?
|
| Age Factors | 2 | 2023 | 1188 | 0.210 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2022 | 36 | 0.210 |
Why?
|
| Menopause | 1 | 2023 | 95 | 0.210 |
Why?
|
| Substance-Related Disorders | 1 | 2023 | 128 | 0.210 |
Why?
|
| Epigenesis, Genetic | 1 | 2023 | 104 | 0.210 |
Why?
|
| Tamoxifen | 1 | 2022 | 59 | 0.210 |
Why?
|
| Receptors, Estrogen | 1 | 2022 | 113 | 0.200 |
Why?
|
| Cytokines | 1 | 2023 | 256 | 0.200 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2022 | 40 | 0.200 |
Why?
|
| Muscle Strength | 1 | 2022 | 161 | 0.200 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2022 | 210 | 0.190 |
Why?
|
| Stress, Psychological | 1 | 2023 | 221 | 0.190 |
Why?
|
| Socioeconomic Factors | 1 | 2022 | 423 | 0.180 |
Why?
|
| Gait | 1 | 2020 | 142 | 0.160 |
Why?
|
| Editorial Policies | 1 | 2018 | 15 | 0.160 |
Why?
|
| Prospective Studies | 4 | 2024 | 2282 | 0.140 |
Why?
|
| Disease Susceptibility | 1 | 2016 | 57 | 0.140 |
Why?
|
| Research Design | 1 | 2018 | 313 | 0.140 |
Why?
|
| Overweight | 1 | 2018 | 280 | 0.130 |
Why?
|
| Retrospective Studies | 1 | 2023 | 3509 | 0.120 |
Why?
|
| Reference Values | 2 | 2024 | 246 | 0.110 |
Why?
|
| Educational Status | 2 | 2023 | 179 | 0.110 |
Why?
|
| Neuropsychological Tests | 2 | 2024 | 371 | 0.100 |
Why?
|
| Animals | 2 | 2024 | 7541 | 0.090 |
Why?
|
| Obesity | 1 | 2018 | 1175 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2018 | 1428 | 0.090 |
Why?
|
| Prevalence | 2 | 2024 | 981 | 0.080 |
Why?
|
| Trail Making Test | 1 | 2023 | 2 | 0.060 |
Why?
|
| Language | 1 | 2024 | 42 | 0.060 |
Why?
|
| Language Tests | 1 | 2023 | 5 | 0.060 |
Why?
|
| Alanine Transaminase | 1 | 2023 | 47 | 0.060 |
Why?
|
| Minnesota | 1 | 2023 | 22 | 0.060 |
Why?
|
| Faculty | 1 | 2023 | 17 | 0.060 |
Why?
|
| Mentors | 1 | 2023 | 31 | 0.060 |
Why?
|
| Feedback | 1 | 2023 | 43 | 0.060 |
Why?
|
| Leadership | 1 | 2023 | 37 | 0.050 |
Why?
|
| alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid | 1 | 2023 | 6 | 0.050 |
Why?
|
| Apolipoprotein E4 | 1 | 2023 | 63 | 0.050 |
Why?
|
| Cholesterol, HDL | 1 | 2023 | 177 | 0.050 |
Why?
|
| United States | 2 | 2024 | 3939 | 0.050 |
Why?
|
| Cholesterol, LDL | 1 | 2023 | 173 | 0.050 |
Why?
|
| Triglycerides | 1 | 2023 | 230 | 0.050 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2022 | 50 | 0.050 |
Why?
|
| Phenotype | 1 | 2023 | 632 | 0.050 |
Why?
|
| Memory | 1 | 2023 | 190 | 0.050 |
Why?
|
| Women's Health | 1 | 2023 | 235 | 0.050 |
Why?
|
| Exercise Therapy | 1 | 2024 | 270 | 0.050 |
Why?
|
| Alcohol Drinking | 1 | 2023 | 249 | 0.050 |
Why?
|
| Residence Characteristics | 1 | 2022 | 191 | 0.050 |
Why?
|
| Incidence | 1 | 2024 | 1199 | 0.050 |
Why?
|
| Peptide Fragments | 1 | 2022 | 399 | 0.040 |
Why?
|
| Voluntary Health Agencies | 1 | 2018 | 2 | 0.040 |
Why?
|
| National Institute on Aging (U.S.) | 1 | 2018 | 8 | 0.040 |
Why?
|
| Prognosis | 1 | 2022 | 1497 | 0.040 |
Why?
|
| Mice | 1 | 2024 | 2484 | 0.040 |
Why?
|
| Behavior Therapy | 1 | 2018 | 103 | 0.040 |
Why?
|
| Periodicals as Topic | 1 | 2018 | 91 | 0.040 |
Why?
|
| Young Adult | 1 | 2024 | 2636 | 0.040 |
Why?
|
| Societies, Scientific | 1 | 2016 | 15 | 0.030 |
Why?
|
| Biomedical Research | 1 | 2018 | 156 | 0.030 |
Why?
|